Boston's Watchman finally gets US green light
This article was originally published in Clinica
Executive Summary
It has been a long road to approval, but Boston Scientific’s Watchman has finally got the go-ahead from the US FDA. The product is designed to close the left-atrial appendage (LAA), a bulge in the wall of the left atrium of the heart where blood clots can form in patients with atrial fibrillation, and therefore prevent ischemic stroke.